Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G/A

Immunic, Inc.

IMUXNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Nov 16, 2026Accepted Nov 16, 2026, 5:58 PM ESTFiling CIK 1280776Accession 0000947871-26-001032
Share

Structured filing — SCHEDULE 13G/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company
Immunic, Inc.
Company CIK
0001280776
Street
1200 Avenue of the Americas
Street (continued)
Suite 200
City
New York
State / country code
NY
Postal code
10036

Statement details

Amendment number
1
Security class
Common Stock, par value $0.0001 per share
Event date
09/30/2026
Rule designation
Rule 13d-1(c)

Reporting person 1

Name
OrbiMed Advisors LLC
Citizenship / organization
DE
Reporting person type
IA
Aggregate amount owned
314,409.00
Percent of class
2.3
Sole voting power
0.00
Shared voting power
314,409.00
Sole dispositive power
0.00
Shared dispositive power
314,409.00
Aggregate excludes certain shares
N

Reporting person 2

Name
OrbiMed Genesis GP LLC
Citizenship / organization
DE
Reporting person type
OO
Aggregate amount owned
314,409.00
Percent of class
2.3
Sole voting power
0.00
Shared voting power
314,409.00
Sole dispositive power
0.00
Shared dispositive power
314,409.00
Aggregate excludes certain shares
N

Reporting person 3

Name
OrbiMed Capital LLC
Citizenship / organization
DE
Reporting person type
IA
Aggregate amount owned
161,395.00
Percent of class
1.2
Sole voting power
161,395.00
Shared voting power
0.00
Sole dispositive power
161,395.00
Shared dispositive power
0.00
Aggregate excludes certain shares
N

Item 1

Issuer

Immunic, Inc.

Principal executive office address

1200 Avenue of the Americas, Suite 200, New York, NY 10036

Item 2

Citizenship

Please refer to Item 4 on each cover sheet for each filing person.

Filing person

OrbiMed Advisors LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC

Principal business or residence address

601 Lexington Avenue, 54th Floor, New York, NY 10022

Item 3

Not applicable indication

N

Type of filing person

IA

Item 4

Percent of class

OrbiMed Advisors LLC: 2.3% OrbiMed Genesis GP LLC: 2.3% OrbiMed Capital LLC: 1.2%

Amount beneficially owned

OrbiMed Advisors LLC: 314,409 OrbiMed Genesis GP LLC: 314,409 OrbiMed Capital LLC: 161,395

Sole voting power

OrbiMed Advisors LLC: 0 OrbiMed Genesis GP LLC: 0 OrbiMed Capital LLC: 161,395

Shared voting power

OrbiMed Advisors LLC: 314,409 OrbiMed Genesis GP LLC: 314,409 OrbiMed Capital LLC: 0

Sole dispositive power

OrbiMed Advisors LLC: 0 OrbiMed Genesis GP LLC: 0 OrbiMed Capital LLC: 161,395

Shared dispositive power

OrbiMed Advisors LLC: 314,409 OrbiMed Genesis GP LLC: 314,409 OrbiMed Capital LLC: 0

Item 5

Not applicable indication

N

Ownership of 5% or less

Y

Item 6

Not applicable indication

N

Ownership on behalf of another person

The Reporting Persons hold 3.5% of the shares of Common Stock in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. OrbiMed Advisors LLC, OrbiMed Genesis GP LLC, and OrbiMed Capital LLC exercise investment and voting power over the shares of Common Stock through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares of Common Stock reported herein.

Item 7

Not applicable indication

Y

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Signature 1

Reporting person
OrbiMed Advisors LLC
Signed
/s/ Carl L. Gordon
Title
Carl L. Gordon / Member
Date
11/16/2026

Signature 2

Reporting person
OrbiMed Genesis GP LLC
Signed
/s/ Carl L. Gordon
Title
Carl L. Gordon / Member
Date
11/16/2026

Signature 3

Reporting person
OrbiMed Capital LLC
Signed
/s/ Carl L. Gordon
Title
Carl L. Gordon / Member
Date
11/16/2026

Filed exhibits

Company context

Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company’s lead development program, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials for the treatment of relapsing multiple sclerosis, with top-line data expected to be available by the end of 2026. Initiation of an additional Phase 3 clinical trial in progressive MS is expected later in 2026. Vidofludimus calcium has already shown therapeutic potential and a favorable safety and tolerability profile in Phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). The company’s development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases. For further information, please visit: www.imux.com.

Current securities

Recent company filings

  1. SCHEDULE 13G - filed by MORGAN STANLEY regarding IMMUNIC, INC.Nov 13, 2026
  2. Results of Operations and Financial ConditionNov 13, 2026
  3. 10-Q filingNov 13, 2026
  4. Regulation FD DisclosureNov 5, 2026
  5. S-8 filingOct 1, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.